Concurrent preoperative eribulin and radiation for resectable retroperitoneal liposarcoma: a phase 1B study
Cancer Treatment and Research Communications · 2026
DOI: 10.1016/j.ctarc.2026.101334 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Cancer Treatment and Research Communications, 2026. Verfasst von Lara E Davis und 16 weiteren Autor:innen. Beteiligte Einrichtung: Sarcoma Program, Clinical Research Division, Fred Hutchinson Cancer Center, 825 Eastlake Ave E, J2-427, Seattle WA, USA. Electronic address: ldavis4@…. Hauptthemen laut MEDLINE: Chemoradiotherapy, Furans, Ketones, Liposarcoma. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Eisai, Oregon Health & Science University Knight Cancer Institute.
Abstract (Originalsprache)
BACKGROUND: Management of retroperitoneal liposarcoma (RPLPS) is challenging and recurrence rates remain high despite aggressive surgical resections. Preoperative radiation alone lacks definitive benefit, thus we sought to evaluate combined chemoradiotherapy with the potential to enhance local efficacy of radiation as well as control micrometastatic disease. We assessed the safety and tolerability of preoperative eribulin, a cytotoxic microtubule inhibitor approved for the treatment of advanced liposarcoma, in combination with radiation in patients with RPLPS. METHODS: In this open-label dose-finding study, patients with primary or recurrent resectable RPLPS received preoperative intensity-modulated radiation therapy (IMRT) with escalating doses of eribulin. Eribulin was administered for three 21-day cycles at a starting dose of 1.1 mg/m2. Concurrent radiation to 50.4 Gy began during cycle 1. Surgical resection occurred 3-10 weeks after completion of chemoradiation. The primary endpoint was determination of the recommended phase 2 doses (RP2D) of concurrent eribulin and radiation. RESULTS: Between 2018-2023, fifteen patients were enrolled. Thirteen patients were evaluable for dose-determination. Four patients treated at starting dose level had no dose-limiting toxicities (DLTs). Two of nine patients treated with escalated eribulin dose had DLTs. The RP2D was established as eribulin 1.4 mg/m2 and IMRT 50.4 Gy. Eleven patients were evaluable for secondary efficacy endpoints. The median recurrence-free survival was 30.4 months (95% CI 12.0-NR) and the median overall survival was 54.1 months (95% CI 9.5-NR). Patient reported outcome data did not show any significant changes over the study period. CONCLUSION: A preoperative chemoradiation protocol of eribulin in combination with IMRT showed a manageable safety profile and warrants additional prospective evaluation for treatment of resectable RPLPS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Sarcoma Program, Clinical Research Division, Fred Hutchinson Cancer Center, 825 Eastlake Ave E, J2-427, Seattle WA, USA. Electronic address: ldavis4@fredhutch.org.
- Knight Cancer Institute, Division of Medical Oncology, Oregon Health & Science University, Portland OR, USA.
- Knight Cancer Institute, Division of Surgical Oncology, Oregon Health & Science University, Portland OR, USA.
- Knight Cancer Institute, Biostatistical Shared Resource, Oregon Health & Science University, Portland OR, USA.
- Advanced Imaging Research Center, Oregon Health & Science University, Portland OR, USA.
- Department of Pathology & Laboratory Medicine, Indiana University, Indianapolis IN, USA.
Förderung
- Eisai
- Oregon Health & Science University Knight Cancer Institute
Zitieren
APA
Davis, L. E., Zhu, L., Mayo, S. C., Latour, E., Park, B., Huang, W., Moloney, B., Davis, J. L., Wakeman, K., Sheppard, B., Billingsley, K. G., Vetto, J., Valenzuela, C. D., Eil, R. L., Rocha, F., Hung, A., & Ryan, C. W. (2026). Concurrent preoperative eribulin and radiation for resectable retroperitoneal liposarcoma: a phase 1B study. Cancer Treatment and Research Communications. https://doi.org/10.1016/j.ctarc.2026.101334
Vancouver
Davis LE, Zhu L, Mayo SC, Latour E, Park B, Huang W, et al. Concurrent preoperative eribulin and radiation for resectable retroperitoneal liposarcoma: a phase 1B study. Cancer Treatment and Research Communications. 2026. doi:10.1016/j.ctarc.2026.101334
BibTeX
@article{Davis2026,
author = {Davis, Lara E and Zhu, Limin and Mayo, Skye C and Latour, Emile and Park, Byung and Huang, Wei and Moloney, Brendan and Davis, Jessica L and Wakeman, Kristina and Sheppard, Brett and Billingsley, Kevin G and Vetto, John and Valenzuela, Cristian D and Eil, Robert L and Rocha, Flavio and Hung, Arthur and Ryan, Christopher W},
title = {Concurrent preoperative eribulin and radiation for resectable retroperitoneal liposarcoma: a phase 1B study},
journal = {Cancer Treatment and Research Communications},
year = {2026},
doi = {10.1016/j.ctarc.2026.101334}
}
EUVIMED